Carboplatin and Sorafenib Tosylate

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

If you are receiving CARBOplatin and SORAfenib together with paclitaxel, you should talk to your doctor to make sure this treatment is appropriate for your condition. When used in the treatment of a specific type of lung cancer known as squamous cell carcinoma, this three drug combination has been associated with an increased rate of death compared to treatment with CARBOplatin plus paclitaxel alone. The reason for this is not clear. It is also uncertain whether these medications may have the same effect in some other types of cancer. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

CONTRAINDICATED: Coadministration of sorafenib in combination with carboplatin and paclitaxel has been associated with an increased risk of death in patients with squamous cell lung cancer. The exact cause has not been identified, and no significant pharmacokinetic changes in any of the three drugs were observed in two phase I clinical studies. A randomized, placebo-controlled trial consisting of 926 chemotherapy-naive patients with unresectable stage IIIB or IV non-small cell lung cancer was stopped early because overall survival was not improved with the addition of sorafenib to a standard carboplatin and paclitaxel regimen. In a subset analysis of the 219 patients with squamous cell carcinoma, increased mortality and decreased progression-free survival were observed with the addition of sorafenib compared to carboplatin and paclitaxel alone. Data in the treatment of other malignancies are limited. Serious toxicities led to the early termination of another study using the same combination to treat advanced ovarian cancer. The study enrolled just 4 patients, but all were ultimately excluded from protocol due to adverse events. Three had life-threatening events (cardiac output failure, myocardial infarction, anastomotic leak), and all required a dosage reduction of sorafenib due to toxicity. In a phase III study of patients with advanced melanoma, sorafenib added to carboplatin and paclitaxel did not increase response rates or progression-free survival as second-line treatment over the two agents alone, but there was an increased incidence of dermatologic adverse events and thrombocytopenia.

MANAGEMENT: The concomitant use of sorafenib with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Caution may be advisable when this combination is used in other malignancies.

Carboplatin

Generic Name: carboplatin

Brand name: Paraplatin, CARBOplatin Novaplus

Synonyms: CARBOplatin

What is Carboplatin?

Sorafenib Tosylate

Generic Name: sorafenib

Brand name: Nexavar

Synonyms: Sorafenib, SORAfenib

What is Sorafenib Tosylate?